Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 27.6% in the afternoon session after the company delivered mixed fourth-quarter 2024 results: It added fewer customers than expected, ...

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

Stocks were mostly lower Tuesday on uncertainty over how much escalating trade tensions and President Donald Trump’s tariff ...

It is bad news for telehealth company Hims & Hers Health (HIMS) today as shares plummeted after its earnings report from yesterday and some ...

Hims & Hers will stop selling generic semaglutide after the FDA said the shortage of GLP-1 medications is resolved.

Hims & Hers (NYSE: HIMS) continues to grow at an astounding rate as the company grows subscribers and revenue per subscriber. But Hims & Hers stock is falling after earnings because investors are ...

Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer healthcare platform said it couldn’t guarantee it would be able to continue ...

With Hims & Her's main source of growth set to be extinguished, Citi analysts said its full-year guidance appears ...

Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...

Hims & Hers (HIMS) stock took a steep dive, dropping more than 27%Tuesday morning — even after the millennial-focused ...

Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...

Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular ...